Pfizer financials
$28.52−0.70%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $62.58B | $63.63B | $59.55B | $101.17B | $81.29B | $41.65B | $40.91B | $40.83B | $52.55B | $52.82B |
| Gross profit | $46.51B | $45.78B | $34.60B | $66.83B | $50.47B | $33.17B | $32.85B | $31.84B | $41.32B | $40.50B |
| Gross margin | 74.3% | 71.9% | 58.1% | 66.1% | 62.1% | 79.6% | 80.3% | 78.0% | 78.6% | 76.7% |
| Operating income | $14.24B | $12.41B | $1.28B | $35.79B | $19.43B | $8.25B | $14.82B | $5.67B | $13.72B | $12.14B |
| Net income | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B | $9.16B | $16.03B | $11.15B | $21.31B | $7.21B |
| Net margin | 12.4% | 12.6% | 3.6% | 31.0% | 27.0% | 22.0% | 39.2% | 27.3% | 40.6% | 13.7% |
| Diluted EPS | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 | $1.63 | $2.82 | $1.87 | $3.52 | $1.17 |
| EBITDA | $24.00B | $21.95B | $10.71B | $43.18B | $28.89B | $14.19B | $13.07B | $12.88B | $20.34B | $19.47B |
| Operating cash flow | $11.71B | $12.74B | $8.70B | $29.27B | $32.58B | $14.40B | $12.59B | $15.83B | $16.80B | $16.19B |
| Free cash flow | $9.08B | $9.83B | $4.79B | $26.03B | $29.87B | $12.18B | $10.54B | $13.84B | $14.85B | $14.37B |
| Diluted shares | 5,713.0M | 5,700.0M | 5,709.0M | 5,733.0M | 5,708.0M | 5,632.0M | 5,675.0M | 5,977.0M | 6,058.0M | 6,159.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.14B | $1.04B | $2.85B | $416.0M | $1.94B | $1.79B |
| Short-term investments | $12.45B | $19.43B | $9.84B | $22.32B | $29.13B | $10.44B |
| Total debt | $64.80B | $64.35B | $71.89B | $35.83B | $38.44B | $39.84B |
| Total assets | $208.16B | $213.40B | $226.50B | $197.21B | $181.48B | $154.23B |
| Total liabilities | $121.39B | $124.90B | $137.21B | $101.29B | $104.01B | $90.76B |
| Shareholders' equity | $86.78B | $88.50B | $89.29B | $95.92B | $77.46B | $63.47B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology